SARTORIUS Stedim Biotech (SSB) is taking over the global sales and marketing of Swiss company Lonza’s cell culture media and buffers used in the manufacture of protein-based therapeutics and vaccines.
As part of the same agreement announced today, Lonza is to continue product development and manufacture, while both companies will work on development of new products.
Lonza’s media is currently sold in liquid or powder form, but is to become available in ready-to-use pre-filled SSB sterile single-use bags.
The co-branding deal means that these will be available under both companies’ brands.
SSM already offers bioreactors and single-use bags and containers, and these new media are considered a good strategic fit into the cell cultivation portfolio.